Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2021 / Cilt: 26 - Sayı: 1

“The Good, the Bad and the Ugly” in the First Year of COVID-19 Pandemic

COVID-19 Pandemisinin Birinci Yılında “İyi, Kötü ve Çirkin”

Pages
12–22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Gaining an overview of the many developments, problems and solution ideas we encountered and witnessed during the pandemic year will make the management of the process easier.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:During the first year of COVID-19 pandemic, while there have been rapid developments in diagnosis and treatment of the disease; drug interactions and side effects have created a problem especially in high risk patients with chronic diseases and multiple drug use.
📊
Key Findings & Data:In contrast to the routine vaccine production process, SARS-CoV-2 vaccines have been developed in a short period of time by many phar-maceutical companies, and community vaccination has started in many countries.
💡
Conclusion & Impact:Gaining an overview of the many developments, problems and solution ideas we encountered and witnessed during the pandemic year will make the management of the process easier.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

During the first year of COVID-19 pandemic, while there have been rapid developments in diagnosis and treatment of the disease; drug interactions and side effects have created a problem especially in high risk patients with chronic diseases and multiple drug use. In contrast to the routine vaccine production process, SARS-CoV-2 vaccines have been developed in a short period of time by many phar-maceutical companies, and community vaccination has started in many countries. However, this process is restricted by mutation and problems in production and distribution. The fact that the pathophysiology of the disease has not been fully elucidated has brought the prolonged COVID-19 syndrome definition to our clinical practice. Positive improvements and negative aspects that we have encountered so far in the first year of this new pandemic reminded us the great film by Sergio Leone: “The Good, The Bad and The Ugly”. So, we decided to cover these aspects under the same headings. Gaining an overview of the many developments, problems and solution ideas we encountered and witnessed during the pandemic year will make the management of the process easier.

Özet

Birinci yılını geride bıraktığımız Coronavirus Disease-2019 (COVID-19) pandemisinde tıp camiasında tanı ve tedavi konusunda hızlı geliş-meler söz konusu iken, kronik hastalığı ve birden çok ilaç kullanan risk faktörü yüksek hastalarda ilaç etkileşimleri ve yan etkileri sorun oluşturmuştur. Rutin aşı üretim sürecinin aksine bir yıl gibi kısa bir sürede birçok ilaç firmasının geliştirdiği aşılar birçok ülkede uygulanmaya başlanmıştır. Ancak bu süreç mutasyon ve üretim ile dağıtımdaki sıkıntılar nedeniyle kısıtlanmaktadır. Hastalığın patofizyolojisinin tam olarak aydınlatılamamış olması uzamış COVID-19 sendromu tanımını gündeme taşımıştır. Pandeminin birinci yılında geldiğimiz noktada “iyi” ve “kötü” gelişmeler olması, bize Sergio Leone’nin yönettiği 1966 yapımı İyi, Kötü ve Çirkin (The Good, The Bad and The Ugly), filmini çağrıştırdı. Biz de pandemide son durumu aynı başlıklar altında incelemeye karar verdik. Pandemi yılında karşılaştığımız ve tanıklık ettiği-miz birçok gelişme, sorun ve çözüm fikirlerine genel bir bakış kazanmak ve fikir elde etmek sürecin yönetimini daha da kolaylaştıracaktır.

🔖

Cite This Article

KAPAR, B., ŞİMŞEK, D., GÜVEN, G. S. (2021). “The Good, the Bad and the Ugly” in the First Year of COVID-19 Pandemic. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 26 - Sayı: 1, 12–22. https://ajindex.com/articles/224325

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. World Health Organization (WHO). Regional Office for Novel Coronavirus (2019-nCoV) Situation Report-51 2020
  2. T.C. Sağlık Bakanlığı COVID-19 Bilgilendirme Sayfası. Genel Koronavirüs Tablosu. Erişim tarihi: 06.02.2021. Erişim adresi: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus- tablosu.html
  3. World Health Organization (WHO). COVID-19. Erişim tarihi: 06.02.2021. Erişim adresi:
  4. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020;94:44-8
  5. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect 2020;80(6):e14-e8
  6. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano 2020;14(4):3822-35
  7. Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 2020;9:72
  8. Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. Heart Rhythm 2020;17(7):e231-e2
  9. Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID- 19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020;9(1):29
  10. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172(9):577-82
  11. Peng PWH, PL Ho, SS Hota. Outbreak of a new coronavirus: what anaesthetists should know. Br J Anaesth 2020;124(5):497-501
  12. Zhang J, Litvinova M, Wang W, Wang Y, Deng X, Chen X, et al. Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study. medRxiv 2020;23:2020.02.21.20026328
  13. Wax RS, MD C. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth 2020;67(5):568-76
  14. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol 2020;92(7):719-25
  15. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020;109(5):531